Telix Pharmaceuticals (NASDAQ:TLX) Given New $20.00 Price Target at HC Wainwright

Key Points

• HC Wainwright lowered the price target for Telix Pharmaceuticals from $23.00 to $20.00 while maintaining a "buy" rating, indicating a potential upside of 107.04% from the current price.
• Several other analysts have given the stock an average rating of "Moderate Buy", with one Hold rating and price targets varying from $20.00 to $22.00.
• The stock saw a 4.0% increase during trading, reaching $9.66, with a current 52-week range from $8.93 to $30.36.

Telix Pharmaceuticals (NASDAQ:TLX - Free Report) had its target price reduced by HC Wainwright from $23.00 to $20.00 in a report published on Wednesday, Marketbeat Ratings reports. HC Wainwright currently has a buy rating on the stock.

Other equities research analysts have also issued reports about the stock. William Blair reiterated an "outperform" rating on shares of Telix Pharmaceuticals in a research note on Wednesday, July 9th. Wedbush restated an "outperform" rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a research note on Thursday, August 28th. Finally, JPMorgan Chase & Co. restated a "neutral" rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 28th. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Telix Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $21.33.

Telix Pharmaceuticals Price Performance

NASDAQ:TLX traded up $0.28 during midday trading on Wednesday, hitting $9.49. 72,854 shares of the company were exchanged, compared to its average volume of 65,239. The company has a fifty day simple moving average of $12.54 and a 200 day simple moving average of $15.39. Telix Pharmaceuticals has a fifty-two week low of $8.93 and a fifty-two week high of $30.36. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.78 and a quick ratio of 2.66.

Hedge Funds Weigh In On Telix Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Private Advisor Group LLC acquired a new position in shares of Telix Pharmaceuticals in the first quarter valued at approximately $170,000. IHT Wealth Management LLC acquired a new position in shares of Telix Pharmaceuticals in the second quarter valued at approximately $213,000. Blair William & Co. IL acquired a new position in Telix Pharmaceuticals during the second quarter worth approximately $217,000. Vanguard Personalized Indexing Management LLC acquired a new position in Telix Pharmaceuticals during the second quarter worth approximately $297,000. Finally, ABC Arbitrage SA acquired a new position in Telix Pharmaceuticals during the first quarter worth approximately $451,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.